

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5847821

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED	10/11/2018
RECEIVING PARTY DATA		
Name:	BLACKTHORN THERAPEUTICS, INC.	
Street Address:	780 BRANNON STREET	
City:	SAN FRANCISCO	
State/Country:	CALIFORNIA	
Postal Code:	94103	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16122780
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	206-622-4900	
Email:	chrisr@seedip.com	
Correspondent Name:	KARL R. HERMANNS	
Address Line 1:	SEED IP LAW GROUP LLP	
Address Line 2:	701 FIFTH AVENUE, SUITE 5400	
Address Line 4:	SEATTLE, WASHINGTON 98104	
ATTORNEY DOCKET NUMBER:	150123.416	
NAME OF SUBMITTER:	KARL R. HERMANNS	
SIGNATURE:	/Karl R. Hermanns/	
DATE SIGNED:	12/03/2019	
Total Attachments: 3		
source=Assignment3#page1.tif		
source=Assignment3#page2.tif		
source=Assignment3#page3.tif		

ASSIGNMENT

WHEREAS,

Corporation Name	Address
Charles River Discovery Research Services UK Limited	Robinson Building, Chesterford Research Park, Saffron Walden, CB10 1XL United Kingdom

(hereinafter referred to as ASSIGNOR), a company incorporated in England and Wales with company registration number 04622227 and having a place of business at the address listed above, is the owner of an invention entitled "VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO," as described and claimed in the specification for which an application for United States letters patent was filed on September 5, 2018, and assigned Application No. 16/122,780; and for which an application was filed on September 5, 2018 with the U.S. Receiving Office of the PCT and assigned Application No. PCT/US2018/049607; both of which applications claim the benefit of U.S. Provisional Application No. 62/554,452, filed on September 5, 2017;

WHEREAS,

Corporation Name	Address
BlackThorn Therapeutics, Inc.	780 Brannon Street, San Francisco, CA 94103

(hereinafter referred to as ASSIGNEE), a corporation of the State of Delaware having a place of business at the address listed above, is desirous of acquiring the entire right, title and interest in and to the invention and in and to any letters patent that may be granted therefor in the United States and in any and all foreign countries;

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR hereby sells, assigns and transfers unto said ASSIGNEE, the entire right, title and interest in and to said invention, said application and any and all letters patent which may be granted for said invention in the United States of America and its territorial possessions including any extensions or adjustments in term thereof and in any and all foreign countries, and in any and all divisions, reissues and continuations thereof, including the right to file foreign applications directly in the name of ASSIGNEE and to claim priority rights deriving from said United States application to which said foreign applications are entitled by virtue of international convention, treaty or otherwise, and including the right to sue and collect damages for past and present infringement of said letters patent; said invention, application and all letters patent on said invention to be held and

enjoyed by ASSIGNEE and its successors and assigns for their use and benefit and of their successors and assigns as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment, transfer and sale not been made. ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks to issue all letters patent on said invention to ASSIGNEE. ASSIGNOR agrees to execute all instruments and documents required for the making and prosecution of applications for United States and foreign letters patent on said invention, for litigation regarding said letters patent, or for the purpose of protecting title to said invention or letters patent therefor.

Charles River Discovery Research Services UK
Limited

11 October 2018
Date



(Signatory Signature) (Assignor)

JACKIE MACRITCHIE DIRECTOR
(Assignor Signatory Name, Title)

I certify that I know or have satisfactory evidence that Jackie Macritchie is the person who appeared before me, and said person acknowledged that he/she signed this instrument on behalf of Charles River Discovery Research Services UK Limited and acknowledged it to be his/her free and voluntary act for the uses and purposes mentioned in the instrument.

11 October 2018
Date

SARAH PRICE
(Name of Witness)

Signed at Saffron Walden, Essex

(Signature of Witness)

Application No. 16/122,780
PCT Application No. PCT/US2018/049607
Assignment-Charles River to BlackThorn

BlackThorn Therapeutics, Inc.

Date

(Signatory Signature) (Assignee)

(Assignee Signatory Name, Title)

Docket No. 150123.416 | Assignment-Charles River to BlackThorn.DOC